Thyroid disease

Incidence of Pediatric Graves’ Disease in the United States: An Epidemiological Analysis of 2007–2022 Outpatient Insurance Claims

ThyroidPublished Retrospective cohort study

Authors' conclusion

This study quantifies and delineates trends in pediatric Graves' disease incidence in the United States. The greatest average incidence rate was observed among female and adolescent patients.

Study context

Population
Pediatric patients diagnosed with GD (ICD-9/ICD-10 codes), Merative Marketscan outpatient insurance claims database, US, 2007–2022
Participants
3,377 new diagnoses
Outcome
Annual incidence of pediatric GD and its trend
Follow-up
2007–2022
Methodological detailsoutpatient insurance claims database
  • Outpatient insurance claims database

Main finding

As reported in the abstract

Average annual incidence of pediatric GD · 16-year study period

Average annual incidence rate

3.33 per 100,000

SD = 0.33

Annual increase in incidence (p = 0.39)

0.042 per 100,000

Observational data: associations, not effects.

Further findings

OutcomeValuesEstimate
Average annual incidence by sexFemalevs MaleSignificantFemale 5.04 per 100,000 · Male 1.67 per 100,000increase in annual incidence (multivariable regression) 1.69 cases per 100,000 (CI 0.82–2.56)
Average annual incidence by age groupAdolescents (13-17 years)vs Other age groupsSignificant; highest of all age groupsAdolescents (13-17 years) 5.72 per 100,000increase in adjusted annual incidence 4.92 cases per 100,000 (CI 3.80–6.04)

Annual incidence by insurance plan, geographic region, rural status

No significant change in annual incidence rate across insurance plan, geographic region, or rural status

Original publication

Incidence of Pediatric Graves’ Disease in the United States: An Epidemiological Analysis of 2007–2022 Outpatient Insurance Claims. Thyroid. Published 22 September 2025. doi:10.1177/10507256251382559

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.